Can you take Tildrakizumab with Vitamin e?

vitamin E has a major potential interaction with Biliary Obstruction.

Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin E. Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions. Vitamin E is metabolized by the liver and primarily excreted in bile and feces. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.

Tildrakizumab has a major potential interaction with History, Tuberculosis.

Do not administer tildrakizumab to patients with active TB infection. It is recommended to assess patients for tuberculosis (TB) infection before starting treatment with this agent. Consider anti-TB therapy prior to initiation of tildrakizumab in patients with latent TB, a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after treatment with tildrakizumab.

Tildrakizumab has a moderate potential interaction with Infection.

The use of tildrakizumab may increase the risk of infection. Treatment with tildrakizumab should not be started in patients with active infection until the infection resolves or is adequately treated. Consider the risks and benefits prior to using this agent in patients with chronic infection or a history of recurrent infection. It is recommended to monitor the patient closely and consider discontinuation of tildrakizumab if a patient develops a clinically important or serious infection or is not responding to standard therapy.

vitamin E has a major potential interaction with Liver Disease.

Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin E. Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions. Vitamin E is metabolized by the liver and primarily excreted in bile and feces. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.

vitamin E has a minor potential interaction with Malabsorption Syndrome.

Vitamin E is readily absorbed from the intestinal tract in the presence of bile. Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E. A water- miscible formulation of vitamin E may be better absorbed in these conditions.

Tildrakizumab has a major potential interaction with Tuberculosis, Active.

Do not administer tildrakizumab to patients with active TB infection. It is recommended to assess patients for tuberculosis (TB) infection before starting treatment with this agent. Consider anti-TB therapy prior to initiation of tildrakizumab in patients with latent TB, a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after treatment with tildrakizumab.

Tildrakizumab has a major potential interaction with Tuberculosis, Latent.

Do not administer tildrakizumab to patients with active TB infection. It is recommended to assess patients for tuberculosis (TB) infection before starting treatment with this agent. Consider anti-TB therapy prior to initiation of tildrakizumab in patients with latent TB, a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after treatment with tildrakizumab.

Tildrakizumab has a moderate potential interaction with Vaccination.

It is recommended to avoid the use of live vaccines in patients treated with tildrakizumab. Before starting therapy with tildrakizumab, consider completion of all age appropriate immunizations according to current immunization guidelines. Care should be exercised as no data are available on the response to live or inactive vaccines.